Condition: Multiple Myeloma · Lymphoma · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma or lymphoma.
This description comes directly from the study's public registry record.
Wei Liu · 86-022-23909282 · liuwei@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Not Yet Recruiting |
| Institute of Hematology & Blood Diseases Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| Tianjin Medical University General Hospital | Tianjin, Tianjin Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05294055